Abbott India Limited (ABBOTINDIA:NSE) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
INR 31,000.00
(+11.84%)
Based on the Abbott India Limited stock forecast from 1 analysts, the average analyst target price for Abbott India Limited is INR 31,000.00 over the next 12 months. Abbott India Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Abbott India Limited is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Abbott India Limited’s stock price was INR 27,718.50. Abbott India Limited’s stock price has changed by +1.34% over the past week, -4.51% over the past month and +15.96% over the last year.
No recent analyst target price found for Abbott India Limited
No recent average analyst rating found for Abbott India Limited
Company Overview Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited. Address: Godrej BKC, Plot C-68, Mumbai, India, 400051 Read Less
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D def...Read More
Frequently Asked Questions About Abbott India Limited (ABBOTINDIA:NSE) Stock
Based on ratings from 1 analysts Abbott India Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and hold ratings.
ABBOTINDIA:NSE stock's dividend yield is 1.51%.
Our analysis grades ABBOTINDIA:NSE stock's dividend yield at A-. This means that ABBOTINDIA:NSE stock's dividend yield is above 90% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this ABBOTINDIA:NSE may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for ABBOTINDIA:NSE is INR 31,000.00 over the next 12 months. The maximum analyst target price is INR 31000 while the minimum anlayst target price is INR 31000.
ABBOTINDIA:NSE stock's Price/Earning ratio is 45.84.
Our analysis grades ABBOTINDIA:NSE stock's Price / Earning ratio at F. This means that ABBOTINDIA:NSE stock's Price/Earning ratio is above 80% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this ABBOTINDIA:NSE may be a overvalued for its sector.
The last closing price of ABBOTINDIA:NSE's stock was INR 27,718.50.
The most recent market capitalization for ABBOTINDIA:NSE is INR 589.66B.
Based on targets from 1 analysts, the average taret price for ABBOTINDIA:NSE is projected at INR 31,000.00 over the next 12 months.
This means that ABBOTINDIA:NSE's stock price may go up by +11.84% over the next 12 months.
We can't find any ETFs which contains Abbott India Limited's stock.
As per our most recent records Abbott India Limited has 3,814 Employees.
Abbott India Limited's registered address is Godrej BKC, Plot C-68, Mumbai, India, 400051.
You can get more information about it from Abbott India Limited's website at https://www.abbott.co.in.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Abbott India Limited (ABBOTINDIA:NSE) Stock
Based on ratings from 1 analysts Abbott India Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and hold ratings.
ABBOTINDIA:NSE stock's dividend yield is 1.51%.
Our analysis grades ABBOTINDIA:NSE stock's dividend yield at A-. This means that ABBOTINDIA:NSE stock's dividend yield is above 90% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this ABBOTINDIA:NSE may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for ABBOTINDIA:NSE is INR 31,000.00 over the next 12 months. The maximum analyst target price is INR 31000 while the minimum anlayst target price is INR 31000.
ABBOTINDIA:NSE stock's Price/Earning ratio is 45.84.
Our analysis grades ABBOTINDIA:NSE stock's Price / Earning ratio at F. This means that ABBOTINDIA:NSE stock's Price/Earning ratio is above 80% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this ABBOTINDIA:NSE may be a overvalued for its sector.
The last closing price of ABBOTINDIA:NSE's stock was INR 27,718.50.
The most recent market capitalization for ABBOTINDIA:NSE is INR 589.66B.
Based on targets from 1 analysts, the average taret price for ABBOTINDIA:NSE is projected at INR 31,000.00 over the next 12 months.
This means that ABBOTINDIA:NSE's stock price may go up by +11.84% over the next 12 months.
We can't find any ETFs which contains Abbott India Limited's stock.
As per our most recent records Abbott India Limited has 3,814 Employees.
Abbott India Limited's registered address is Godrej BKC, Plot C-68, Mumbai, India, 400051.
You can get more information about it from Abbott India Limited's website at https://www.abbott.co.in.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ABBOTINDIA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
